The new TrueBeam™ system from Varian Medical Systems is the latest and one of the most advanced radiotherapy technologies in the world for treating cancer. Developed from the ground up it optimizes both radiotherapy and radiosurgery treatments. TrueBeam delivers more flexible cancer treatments with pinpoint accuracy and precision, ease and speed.
TrueBeam can treat cancers anywhere in the body, where radiation treatment is indicated. TrueBeam technology opens the door to new possibilities for the treatment of challenging cases such as cancers in the lung, breast, abdomen, and head and neck as well as other cancers that are treatable with radiotherapy. Check with your doctor to see if TrueBeam treatment is appropriate for your specific cancer.
TrueBeam rotates around the patient to deliver a prescribed radiation dose from nearly any angle. It combines imaging, beam delivery and sophisticated RapidArc technology to accurately and precisely target tumors with great speed. Real-time imaging tools allow clinicians to "see" the tumor they are about to treat and respiratory gating enables clinicians to synchronize beam delivery with patient respiration.
New technology enables a radical new approach that expands radiotherapy treatment options for even the most challenging cases
New York, NY - April 14, 2010 - Varian Medical Systems (NYSE:VAR) today is announcing the introduction of a new line of "super" accelerators designed to advance the treatment of lung, breast, prostate, head and neck, and other types of cancer. The TrueBeam™ platform for image-guided radiotherapy and radiosurgery is the first fully-integrated system designed from the ground up to treat a moving target with unprecedented speed and accuracy. Varian unveiled the new line last night at a special event conducted here for members of the cancer treatment community.
"We took everything clinicians told us they wanted to enable next-generation treatments, and we challenged ourselves to engineer a completely new treatment platform," said Tim Guertin, president and CEO of Varian Medical Systems. "TrueBeam is the culmination of those efforts." A TrueBeam system uses a completely re-engineered control system and a multitude of technical innovations to dynamically synchronize imaging, patient positioning, motion management, and treatment delivery. "It opens the door to the development of new and improved approaches for treating cancer and other medical conditions commonly treated with image-guided radiotherapy and radiosurgery," Guertin said. "We've also given TrueBeam a patient-friendly look with a beautiful sleek design, but it's what's under the covers that makes this system so special. It's intuitive, intelligent, and we think it is a game changer."
Designed to be a versatile platform, a TrueBeam system can be used for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy. The product line includes TrueBeam STx, specially configured for advanced radiosurgery.
A TrueBeam system can deliver treatments up to 50 percent faster with a dose delivery rate of up to 2400 monitor units per minute, double the maximum output of earlier, industry-leading Varian systems. This makes it possible to offer greater patient comfort by shortening treatments, and to improve precision by leaving less time for tumor motion during dose delivery.
"Intelligent" automation further speeds treatments with an up to five-fold reduction in the number of steps needed for imaging, positioning and treating patients. A standard intensity-modulated treatment that would typically take ten minutes can be completed in less than two minutes. Complex radiosurgery that typically takes 40 minutes to an hour, can be completed in just 5 to 20 minutes. "When we introduced RapidArc® radiotherapy, we were thrilled to see treatments done in about 2 minutes," said Guertin. "With TrueBeam, RapidArc treatments can now be completed in about a minute."
The precision of a TrueBeam system is measured in increments of less than a millimeter. This accuracy is made possible by the system's sophisticated architecture, which establishes a new level of synchronization between imaging, patient positioning, motion management, beam shaping, and dose delivery technologies, performing accuracy checks every ten milliseconds throughout an entire treatment. Over 100,000 data points are monitored continually as a treatment progresses, ensuring that the system maintains a "true isocenter," or focal point of treatment
"This increased level of precision will make it possible for doctors to treat a moving lung tumor as if it were standing still," said Guertin. "By synchronizing treatment with tumor position changes throughout the respiratory cycle, doctors will be able to reduce the margin of healthy tissue affected by the treatment beam."
The TrueBeam system also delivers Varian's new 'gated' RapidArc radiotherapy, which compensates for tumor motion by synchronizing imaging with dose delivery during a continuous rotation around the patient. "This exciting new capability makes RapidArc an even more powerful tool for treating cancers of the thorax, such as lung and liver cancer, when tumor motion is an issue," Guertin said. Other innovations built in to the TrueBeam system include:
"With its many new unmatched capabilities, we've created a new breed of accelerator with the versatility to improve conventional treatments and at the same time support the clinical development of treatment innovations that offer patients more options for fighting their disease," said Guertin. "TrueBeam takes us a significant step closer towards our goal of helping to save 100,000 more lives each year."
Some of the motion management tools developed for the new TrueBeam system have been added to Varian's Trilogy platform and are being made available to customers with Clinac® iX accelerators. "As we develop new capabilities for this system, we'll use what we learn to continually enhance our full line of treatment solutions, ensuring that we can continue to offer the widest spectrum of advanced solutions for meeting our diverse customers' needs," Guertin said.
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,000 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.
RapidArc® radiotherapy technology is a major advance from Varian Medical Systems that improves dose conformity while significantly shortening treatment times. RapidArc delivers treatments two to eight times faster than our fastest dynamic treatments today and increases precision - a winning combination that enables physicians to improve the standard of care and treat more patients.
RapidArc is a volumetric arc therapy that delivers a precisely sculpted 3D dose distribution with a single 360-degree rotation of the linear accelerator gantry. It is made possible by a treatment planning algorithm that simultaneously changes three parameters during treatment:
Volumetric modulated arc therapy differs from existing techniques like helical IMRT or intensity-modulated arc therapy (IMAT) because it delivers dose to the whole volume, rather than slice by slice. And the treatment planning algorithm ensures the treatment precision, helping to spare normal healthy tissue.
Organ conservation in the practice of Oncology has been a topic of hot debate in the western countries for the past few decades. At Chennai Cancer Care, we consider the practice of organ conservation wherever feasible without compromising the Control & Cure rates.There are a very few sites in Oncology where this practice could be considered without compromising the results with the added advantage of organ conservation. Those sites include Breast tumors, Head and neck tumors and Bone tumors.
This is made possible with availability of multimodal (or) multidisciplinary approach. Availability of latest Chemotherapy, Targeted therapy drugs, Surgical and Radiation Therapy expertise have done wonders in this modern era of medicine. Removal of the whole breast is not warranted or needed as this causes a major psychological impact in woman and studies point towards the fact that most women who undergo Modified Radical Mastectomy (MRM) or Removal of breast had a sense of feeling that they have lost the feminity in them, whereas some consider loss of breast, a social taboo and reduced their social activities. All these psychological facts point towards BCT and its advantage
The commonest sites in head and neck, where organ conservation could be considered are buccal mucosa, tongue and laryngeal cancers. Removal of a portion of tongue will impair the person's speech. Removal of Vocal Cords will impair the person's voice pattern or quality of voice whereas conserving these organs and with radiation therapy to these sites, results were comparable to that of Surgical Excision. Interstitial implants or Brachytherapy is a standard practice in early stage Oral cavity or Pharyngeal malignancies.
Ancient treatment technique like Interstitial Brachy therapy with modern refinement - High dose rate (HDR) Brachytherapy, has revolutionized cancer therapy. In Brachy therapy implants, Radioactive sources are placed at the tumor site or tumor bed to deliver a Booster Dose to that site which in turn increases the Tumor local control rates and hence Tumor free survival
Dr.S.Alex A Prasad has specialized in Brachytherapy and is the only Brachytherapist trained in Tata Memorial Hospital, Mumbai & The Christies Hospital, Manchester, UK.
Organ (limb) conservation has been made possible without altering the tumor control rates. The most common bone tumors treated in this part of our country are Osteosarcoma and Ewings Sarcoma which usually affect the adolescent age group. Should we not consider the option of limb conservation considering the age?
PNo: 107A, New Avadi Road, Kilpauk, Chennai – 600 010 Phone: 044-42858850, 044-42858050, 8939855577 |
For Order & Home Delivery :+91 90 9444 0304, 044 4285 8850 |
Branch Address |
|
No.2/2028 H block |
New no 34, Old no 92 |
Our Delivery Partner |
|
Chemotherapy is given for the following reasons:
IMRT/ IGRT is a "State of the Art Cancer Treatment" that delivers high doses of radiation directly to cancer cells in a very targeted way. IMRT/IGRT .